ArticleEuropean journal of drug metabolism and pharmacokinetics2015
Pharmacokinetics and toxicity of repeated oral etoposide is altered by morphine coadministration in rats.
Article in European journal of drug metabolism and pharmacokinetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Morphine poisoning in a patient with malignant peritoneal mesothelioma: A case report.Experimental and therapeutic medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influence of morphine (MOR) on the pharmacokinetics and toxicity of repeated etoposide (ETP) oral administration was evaluated in rats. A decrease in the number of leukocytes in blood was observed by 5 days of treatment with ETP (30 mg/kg/day), which was prolonged by oral MOR coadministration (30 mg/kg/day). Furthermore, MOR significantly decreased animal viability. During the dosing period, the individual plasma ETP concentrations decreased at every dose. These doses were used to estimate the individual pharmacokinetic parameters by the Bayesian method using a linear 2-compartment model with a first-order kinetic absorption and the population parameters reported in our previous study. As a result, repeated ETP dosing without MOR showed a significant decrease in the intestinal absorption rate constant (ka), and single MOR coadministration induced an increase in bioavailability (F) and decrease in ka. However, repeated coadministration of ETP suppressed the increase of F by MOR, and the dose-normalized area under the concentration-time curve was not significantly decreased. The estimated trough concentration in the final day of coadministration was significantly higher than that of the control treatment and indicated a prolonged exposure time. These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.